With traditional NGS, long turnaround times (TAT) of 4+ weeks and high failure rates due to quantity not sufficient (QNS) are common. The Ion Torrent™ Genexus™ System is a better testing solution: it decreases TAT to as little as 1 day from sample to results,* and essentially eliminates QNS failure, achieving success using tissue samples as small as 10 ng. Join us to learn how the Genexus System can improve your lab’s efficiency and increase your testing success rates.
By the conclusion of this session you will understand:
1. Understand the value of the Genexus in a post-pandemic environment
2. Explore the financial & operational impacts of the Ion Torrent Genexus™ System for in-house
This virtual meeting will be conducted within OncomineWorld in our virtual auditorium. OncomineWorld is so much more than your traditional virtual event – you can navigate to many different areas and experience a new level of virtual interactivity. Within OncomineWorld you can…
* Specimen-to-report workflow will be available after the Ion Torrent™ Genexus™ Purification System and integrated reporting capabilities are added in 2021.
Andy is currently the Vice President of Product Management and Market Development for the Clinical Sequencing Division, responsible for the development and launch of all products related to Ion Torrent NGS systems. Andy began his career at Applied Biosystems, UK team in 1994 after completing an undergraduate degree in Chemistry at Liverpool (JM) University and a PhD focused on peptide fragments of Epidermal Growth Factor at Oxford Brooks University. In 1997 he moved to corporate headquarters in California and entered Product Management. During this time Andy was responsible for a number of product lines and launches, including the launch of the 7300/7500 and 7500 Fast Real Time PCR Systems, and the 3500 and 3500 Dx Genetic Analyzers, eventually becoming the Director of the Capillary Electrophoresis business. Andy joined Ion Torrent in June 2010 during its start-up phase and subsequent purchase by Life Technologies.
Kevin is currently the Associate Director of the Molecular Pathology and Cytogenetics laboratories at Cedars-Sinai Medical Center, Department of Pathology & Laboratory Medicine. Kevin has worked at Cedars-Sinai for more that thirty years as a Clinical Laboratory Scientist. He has a Specialist Certification in Immunology from the ASAP and received his Master's in Public Health from UCLA. Kevin has been involved with molecular testing for more than 20 years. His current role is to oversee operations and testing in the Molecular Pathology and Cytogenetics laboratories.
Dr. Vail is currently the Director of Molecular Pathology at Cedars-Sinai Medical Center, responsible for the administration, development and validation of all clinical molecular diagnostics at CSMC. Dr. Vail recived his MD from St. George's University. In 2017 he completed his AP/CP residency at New York Medical College and subsequently finished a Molecular Genetic Pathology fellowship at CSMC. Dr. Vail's primary research focus is in the utilization of clinical sequencing in cancer and (more recently) the local genomics of SARS-CoV-2.
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events